RBC Capital analyst Trung Huynh raised the firm’s price target on Eli Lilly to $580 from $490 and keeps an Outperform rating on the shares. Q2 sales came in 10% ahead of expectations and guidance was upgraded following the “impressive” Q2 results, the analyst tells investors. Following the report and guidance, the firm now forecasts 7% higher FY23 revenues of $33.6B and 11% higher adjusted EPS of $9.85.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Lilly Completes Acquisition of DICE Therapeutics
- Novo Nordisk, Eli Lilly news positive for Terns Pharmaceuticals, says Mizuho
- Cantor biotech/biopharma analysts to hold analyst/industry conference call
- Eli Lilly price target raised to $630 from $550 at Cantor Fitzgerald
- Eli Lilly price target raised to $615 from $500 at Wells Fargo